INTRODUCTION
The Pediatric Eye Disease Investigator Group (PEDIG) is a coordinated group of over 60 clinics (over 120 pediatric ophthalmologists and optometrists) across North America looking to review scientifically pediatric eye disorders and the traditional treatment thereof. Over the last three years, they have looked more specifically at the treatment of amblyopia, with eight major studies called Amblyopia Treatment Studies (or ATS) numbers 1 through 8.
ATS STUDIES

ATS1
1 looked at a randomized trial of using 1% atropine vs. 2 to 6 hours of occlusion therapy a day for treatment of moderate amblyopia. Children between ages 3 and 7 years old with moderate amblyopia (defined as 20/40 to 20/100, or > 3 lines difference between the visual acuity of both eyes) and with vision in the sound eye > 20/40 were placed in one of two groups: treatment with atropine 1% or treatment with patching. Vision was tested using an electronic visual acuity tester with single surround HOTV optotypes. Both strabismic and anisometropic amblyopic patients were included. For hyperopic patients who showed little success with treatment after 16 weeks, the lens over the sound eye was reduced to plano for further optical penalization. After six months of treatment, the investigator was to decide whether the patient should continue in the same group or be switched to the other group (approximately 25% of patients were switched to the alternative form). Patients were followed for a total of two years.
Results at the six-month 2 and two-year 3 mark were similar in both groups suggesting that atropine and part-time occlusion therapy had the same effect for initial treatment of moderate amblyopia in children aged 3 to 7 years. Of note, however, was that while the end result was the same, visual improvement appeared to be faster in the patching group. In Kushner's discussion 4 he also pointed out that the end criteria for success was 20/30 in the study, but if a visual acuity of 20/25 was considered successful, 40% of the patching group achieved this vs. only 28% of the atropine group. Similar results were presented at William Scott's 2005 Marshall Parks lecture at the American Academy of Ophthalmology meeting. He reported in his retrospective chart review, that he had found that full-time patching for amblyopia led to 50% of his patients achieving 20/20, 96% achieving > 20/30, and 97% achieving > 20/40. 5 With patients with strabismic amblyopia, ATS1 also showed that amblyopia therapy is associated with deterioration of alignment from orthotropia, with a 14% risk of microstrabismus (16% in the patching group, 10% in the atropine group), and a 3% risk of a > 8 Δ tropia. Amblyopia therapy alone was associated with a 14% chance of resolution of a tropia > 8 Δ , and a 36% chance of any resolution at least to a microtropia. Atropine was found to cause an improvement in visual outcome even without seeing a fixation switch to the amblyopic eye when the good eye was blurred with atropine.
ATS8 (in progress) follows from ATS1 and compares weekend atropine treatment augmented with a plano lens to the sound eye vs. weekend atropine alone.
The next study, ATS2 6,7 looked at patching regimes for either severe (20/100-20/400) or moderate (20/40-20/80) amblyopia in children 7 years old or younger. It compared two hours vs. six hours of patching in moderate amblyopes, and full-time patching vs. six hours of patching for severe amblyopia. One hour of near visual activity was recommended each day. Results were reported after four months of treatment.
In the severe amblyopia group (ATS2a), it was concluded that amblyopia improved with both six hours a day patching and fulltime patching when combined with prescribed near work. In the moderate amblyopia group (ATS2b), it was concluded that amblyopia improved with both two and six hours of part-time occlusion when combined with one hour of prescribed near work. The rate and magnitude of improvement was also equal.
An amblyopia recurrence study (ATS2c) 8 then followed 156 children under the age of 8 years with successfully treated amblyopia who had discontinued their treatment.
Recurrence of amblyopia overall during the one year follow-up was about 22%. This was similar in both the atropine and the patching groups. While there was a suggestion that this was not a randomized trial, the data does hint in favor of the benefit of weaning patients from patching vs. stopping the use of atropine altogether. ATS6 9 is still currently underway and furthers the findings of ATS2 comparing near vs. distance activities while patching for amblyopia. ATS3 10,11 examined treatment of amblyopia in children aged 8 to 18 years with the objective of determining the response rate to treatment in older children. It also looked at the frequency of recurrence of successfully treated amblyopia in the 7 to <18 year-old age group. Patients were to have had no amblyopia management other than glasses in the month prior to treatment, and no more than one month of amblyopia therapy in the previous six months. Five hundred seven children were divided into a control group of glasses alone, and an active group of prescribed glasses and 2 to 6 hours of patching or daily atropine with one hour of near work. The atropine treatment was restricted to the children younger than 13 years as it was felt to be too dangerous to blur the good eye of older children because of their activity requirements.
The results showed that amblyopia improved with optical correction alone in 1/4 of patients. Patients aged 7 to 12 years with active amblyopia therapy (patching/ atropine) can improve vision even with prior amblyopia treatment. ATS4 12 reviewed daily vs. weekend (or two days) atropine regimes for treatment of moderate amblyopia (20/40-20/80) in 168 children aged 3 to 6 years. After four months, results showed weekend atropine was as effective as daily atropine in treating moderate amblyopia in this age group. The visual improvement was similar to that seen with two to six hours of patching for moderate amblyopia reported in ATS2.
ATS5 (in progress) is comparing two hours of daily patching vs. a control group of spectacle therapy alone. At the last AAPOS meeting, Steele et al. 13 reported that they had found anisometropic amblyopia could be treated with spectacle correction alone. They found that the best candidates were < 5 years and with 1 to 2 D of hyperopic anisometropia and mild to moderate amblyopia. Furthermore, they found a lower recurrence rate (14%) for amblyopia after treatment with glasses alone compared to recurrence rates reported after treatment with occlusion or atropine (24-26%).
ATS7 (in progress) follows the time course of visual improvement of children with bilateral refractive amblyopia.
STUDY DESIGN
A recent article 14 in J AAPOS attempted to report on members' applications of the PEDIG studies by asking ophthalmologists, via mail questionnaire, if and how these studies had changed their treatment regimes. The response rate was somewhat poor. We conducted a similar survey at the start of an ATS review lecture at a pediatric ophthalmology conference in Vancouver, B.C., Canada. Our survey had six ATS related questions. This was in no way a statistically accurate analysis, but rather an informal way of assessing the penetration of the PEDIG recommendations into typical pediatric ophthalmology practices. There were 66 questionnaires answered. The audience was composed mainly of pediatric ophthalmologists and orthoptists from B.C. and western Canada with a few from other areas of Canada and the United States.
RESULTS
The questions and responses are shown in Tables 1-6 . (Percentage of practitioners responding positively to an answer denoted in brackets.)
DISCUSSION
The results indicate that most of us in Canada are still using patching as the first method of amblyopia treatment. Atropine is seen as a reasonable alternative and we use it more now in noncompliant patients. If atropine is used, it is more likely to be used daily rather than just on weekends. Nearly all who use patches would patch more than two hours/day and the majority would begin patching more than four hours/day in patients with moderate amblyopia. Two-thirds would patch six hours/day or more for patients with severe amblyopia. The majority (83%) use near work exercises as part of amblyopia treatment while patching. Sixty percent feel that patching can be successful to age 12 years and another 25% think it may be useful to age 14 years.
We still favor patching and use it in 95% of our practice. We find that if we present families with the chance of a more rapid amblyopia resolution, coupled with a chance of a higher visual acuity as an end point and also mention the rare although present systemic risks associated with atropine, parents do agree to try patching first. We encourage longer hours of patching and longer observation times in newly treated older amblyopic patients as we have had some spectacular improvements in older amblyopic patients whose condition has been late in detection and who have been previously untreated. We start patients with moderate amblyopia on two hours/day of patching, but if there is an inadequate response we increase the length of time. We think it is reasonable to start patients with severe amblyopia on six hours/day of patching. We also suggest one hour/day of near work.
CONCLUSION
In spite of numerous studies published by the PEDIG, we found in our survey that most ophthalmologists and orthoptists in Canada still continue to use patching as the primary treatment for amblyopia. It appears that although the PEDIG studies are interesting and have stimulated thought, personal experience and past teaching still guide our approach to amblyopia treatment.
